Lymphoma clinical trials
The registry lists 3,018 studies for Lymphoma across more than 10 countries. 433 are recruiting or about to start. 1,042 of them are mainly about Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 21 narrower conditions too, such as Lymphoma, Non-Hodgkin: 8,682 studies, 1,877 open.
ClinicalTrials.gov finds 11,356 studies for Lymphoma. How that becomes 3,018 here
This page counts the studies the registry files under Lymphoma, and those it files under no condition that list Lymphomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count
- 11,356Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −5,660Filed under a narrower condition, counted on its own pageLymphoma, Non-Hodgkin 1,556 · Lymphoma, Follicular 981 · Lymphoma, Large B-Cell, Diffuse 751 · Lymphoma, B-Cell 404 · Hodgkin Disease 349 · Lymphoma, Mantle-Cell 268 · 13 more
- −874List Lymphoma as a condition, but the registry did not file them under itMost often written as “Small Lymphocytic Lymphoma” (114), “Primary Central Nervous System Lymphoma” (55), and “Lymphoblastic Lymphoma” (40). The registry filed 246 of them under no condition at all, and the others under other conditions only, most often Leukemia, Lymphocytic, Chronic, B-Cell (219) and Precursor Cell Lymphoblastic Leukemia-Lymphoma (117).
- −1,804Match it another way354 name it in the title, 62 in a keyword, and 1,388 by a synonym or other text the search reads.
- 3,018The count on this page
Get an email when these change. Save the Lymphoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (170) · M.D. Anderson Cancer Center (153) · Memorial Sloan Kettering Cancer Center (99) · Alliance for Clinical Trials in Oncology (45) · Children's Oncology Group (35) · SWOG Cancer Research Network (34) · Fred Hutchinson Cancer Center (32) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (32)
What is being tested here
Drugs under test in Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Rituximab | 11 | 28 | 253 |
| Venetoclax | 11 | 0 | 16 |
| Cyclophosphamide | 10 | 13 | 179 |
| Fludarabine | 8 | 4 | 106 |
| Lenalidomide | 6 | 4 | 47 |
| Glofitamab | 5 | 1 | 8 |
| Epcoritamab | 5 | 2 | 8 |
| Immunoglobulins, Intravenous | 5 | 4 | 5 |
| Immunoglobulin G | 5 | 4 | 5 |
| Doxorubicin | 4 | 9 | 56 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 18 open · Antimetabolites 16 open · Immune checkpoint inhibitors 16 open · Alkylating agents 14 open · Corticosteroids 7 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Post-Op Pain Control for Prophylactic Intramedullary Nailing. · Phase 3 · St. Louis University
- Jan 2027A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL · Phase 3 · Xia Yi
- Feb 2027A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) · Phase 3 · Acerta Pharma BV
- Feb 2027Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy · Phase 3 · Peking University First Hospital
- Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 3 · Monash University
- Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 3 · Monash University
- Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) · Phase 3 · Monash University
- Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) · Phase 3 · Monash University
- Apr 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension · Phase 3 · Monash University
- May 2027Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial · Phase 3 · University of Rochester
Who these studies take
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger. 77 (22%) take children under 18. 4 (1%) are for women only and 0 (0%) for men only; 20 (6%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 54 (16%) | 53 (15%) |
| 18 | 317 (92%) | 314 (91%) |
| 30 | 317 (92%) | 314 (91%) |
| 40 | 314 (91%) | 311 (90%) |
| 50 | 309 (89%) | 308 (89%) |
| 65 | 313 (90%) | 312 (90%) |
| 75 | 291 (84%) | 290 (84%) |
| 85 | 256 (74%) | 255 (74%) |
Across all 3,018 studies, recruiting or not: 29% stop at 75 or younger and 17% at 65; 26% take children; 1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Lymphoma studies take
Of 293 phase 2 interventional studies under Lymphoma, half reached primary completion within 61 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 53 mo34–77 · 281 studies | 44 mo24–61 · 143 studies | 64 mo39–88 · 138 studies |
| Phase 1/2 | 74 mo48–111 · 143 studies | 65 mo41–87 · 66 studies | 79 mo49–133 · 77 studies |
| Phase 2 | 61 mo36–105 · 293 studies | 36 mo26–65 · 56 studies | 67 mo42–114 · 237 studies |
| Phase 3 | 67 mo52–106 · 62 studies | 57 mo52–69 · 29 studies | 89 mo59–116 · 33 studies |
| Interventional, no phase | 43 mo23–87 · 170 studies | — | 44 mo25–87 · 161 studies |
| Observational | 82 mo39–269 · 159 studies | — | 90 mo41–269 · 140 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
- Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.Oct 29, 2026NCT07518329
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaOct 22, 2026NCT07711483
Results posted3
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaNov 12, 2026NCT04739813
- Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular LymphomaOct 28, 2026NCT05410418
- Observational Study of People Living With HIV Treated With CD19-directed CAR T CellOct 28, 2026NCT05784415
Newly registered7
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized TrialNov 3, 2026NCT07912684
- Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and LymphomaNov 3, 2026NCT07914348
- Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell CytopeniasOct 26, 2026NCT07895017
- Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic LeukemiaOct 20, 2026NCT07882069
- A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell LymphomaOct 20, 2026NCT07882576
Show 2 moreShow fewer
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasOct 20, 2026NCT07883135
- Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.Oct 20, 2026NCT07883941
Studies
Recruiting first, then most recently updated. Showing 50 of 3,018. Browse all 3,018 → or search them.
- A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)RecruitingNCT07221500Phase 25 countries
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingNCT07524530Phase 21 country
- Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic MalignanciesRecruitingNCT050110451 country
- A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and LymphomaRecruitingNCT03829254Phase 1/21 country
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 21 country
- Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in TexasRecruitingNCT05676450Not applicable1 country
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingNCT02974647Phase 21 country
- Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingNCT03934372Phase 1/27 countries
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)RecruitingNCT02332668Phase 1/29 countries
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingNCT04301076Phase 11 country
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/21 country
- Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in DLBCL Across the UKCHART NetworkNot yet recruitingNCT07813585
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)RecruitingNCT009235071 country
- Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.RecruitingNCT06218602Phase 21 country
- A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell LymphomasRecruitingNCT05773040Phase 11 country
- A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront TherapyRecruitingNCT06510361Phase 21 country
- A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasRecruitingNCT07018752Phase 1/21 country
- Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by invitationNCT032267041 country
- Living Well With LymphomaRecruitingNCT06047626Not applicable1 country
- Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantRecruitingNCT068562261 country
- Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyRecruitingNCT052379861 country
- The CARDIOPROTECT TrialNot yet recruitingNCT07654426Phase 21 country
- A Phase I Dose Finding Study of MB-CART2219.1RecruitingNCT07108868Phase 11 country
- Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaRecruitingNCT07249905Phase 1/23 countries
- HPC Offered for PRESERVE ExpansionRecruitingNCT071454111 country
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingNCT06084936Phase 313 countries
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaRecruitingNCT07015242Phase 23 countries
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruitingNCT053668811 country
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyRecruitingNCT07188558Phase 33 countries
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized TrialRecruitingNCT07912684Not applicable1 country
- Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and LymphomaRecruitingNCT07914348Phase 11 country
- IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasRecruitingNCT05365659Phase 15 countries
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT06520098Phase 21 country
- Mosaic Trial for Stem Cell Transplant RecipientsRecruitingNCT06960993Not applicable1 country
- More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)RecruitingNCT07705178Not applicable1 country
- Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)RecruitingNCT05371132Phase 11 country
- Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaRecruitingNCT07583810Phase 21 country
- Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.RecruitingNCT07518329Phase 11 country
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT061318011 country
- REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEsRecruitingNCT05223413Not applicable6 countries
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyRecruitingNCT04570423Phase 21 country
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT011376431 country
- A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received BlinatumomabRecruitingNCT074223371 country
- HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable1 country
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 21 country
- Collection of Tissue Samples for Cancer ResearchRecruitingNCT009001982 countries
- Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic ChemotherapyRecruitingNCT05921253Early Phase 11 country
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsRecruitingNCT06441331Phase 13 countries
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/21 country
- Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell CytopeniasNot yet recruitingNCT07895017Phase 21 country